Applicant, as named in the Orange Book
Eisai Inc
Next listed expiry: Halaven on 8 Jul 2027. 3 products with live protection, 4 without.
Products with listed protection
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Halaven eribulin mesylate | eribulin mesylate | 201532 | 8 Jul 2027 | patent |
| Dayvigo · 2 strengths lemborexant | lemborexant | 212028 | 21 Oct 2035 | patent |
| Lenvima · 2 strengths lenvatinib mesylate | lenvatinib mesylate | 206947 | 15 Nov 2038 | patent |
Recent events
- 25 Oct 2026Halaven · Generic approved 19 Oct 2026
- 25 Oct 2026Halaven · Generic approved 1 Jun 2026
- 25 Oct 2026Halaven · Generic approved 16 Mar 2026
- 24 Oct 2026Halaven · Enters 12-month window basis: patent8 Jul 2027
Products without listed protection (4)
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Aricept donepezil hydrochloride | donepezil hydrochloride | 022568 | open now | no listed protection |
| Aricept · 2 strengths donepezil hydrochloride | donepezil hydrochloride | 020690 | open now | no listed protection |
| Banzel rufinamide | rufinamide | 201367 | open now | no listed protection |
| Banzel · 2 strengths rufinamide | rufinamide | 021911 | open now | no listed protection |